Research programme: histamine H3 receptor antagonists - Pfizer

Drug Profile

Research programme: histamine H3 receptor antagonists - Pfizer

Alternative Names: 475071; WAY 361563; WAY-361046; WAY-364416

Latest Information Update: 29 Sep 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Wyeth
  • Developer Pfizer
  • Class Amines; Small molecules
  • Mechanism of Action Histamine H3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cognition disorders; Schizophrenia

Most Recent Events

  • 21 Oct 2009 Preclinical trials in Schizophrenia in USA (PO)
  • 21 Oct 2009 Pharmacodynamics data from a preclinical trial in Schizophrenia presented at the 39th Annual Meeting of the Society for Neuroscience (SfN-2009)
  • 15 Oct 2009 Wyeth has been acquired by Pfizer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top